| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454077 | Lung Cancer | 2018 | 6 Pages |
Abstract
Tumor biomarker testing using clinical NSCLC specimens in routine oncologic care evolves rapidly following approval of targeted therapies linked to diagnostic assays. Our practice's decade plus experience highlights the rapid evolution of biomarker testing and confirms the therapeutic relevance of such testing in all patients-particularly those patients with light/no history of tobacco use.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul A. VanderLaan, Deepa Rangachari, Adnan Majid, Mihir S. Parikh, Sidharta P. Gangadharan, Michael S. Kent, Danielle C. McDonald, Mark S. Huberman, Susumu S. Kobayashi, Daniel B. Costa,